Serum Thromboxane B2 Compared to Five Other Platelet Function Tests for the Evaluation of Aspirin Effect in Stable Cardiovascular Disease

Heart Lung and Circulation

Volumn 19, Issue 4, 2010, Pages 234-242

  Kidson Gerber, Giselle ^a,b   Weaver, James ^b,c   Gemmell, Rosalie ^c   Prasan, Ananth M ^b,c   Chong, Beng Hock ^b,c  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

Author keywords

Aspirin; Clopidogrel; Drug resistance; Fish oils; Platelet function tests; Thromboxane B2

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ARACHIDONIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 FATTY ACID; THROMBOXANE B2; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FISH OIL; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; HEMATOCRIT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PREDICTION; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; TREATMENT OUTCOME; TURBIDIMETRY; BLOOD; BLOOD PRESSURE; CASE CONTROL STUDY; COMPARATIVE STUDY; DRUG EFFECT; MIDDLE AGED; NONPARAMETRIC TEST; QUESTIONNAIRE; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; FISH OILS; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; QUESTIONNAIRES; STATISTICS AS TOPIC; STATISTICS, NONPARAMETRIC; THROMBOXANE B2; TICLOPIDINE;

EID: 77649232258     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlc.2009.11.002     Document Type: Article

References (33)

1. de Gaetano G., and Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 357 (2001) 89-95
2. Aspirin Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308 (1994) 81-106
3. Krasopoulos G., Brister S., Beattie W., and Buchanan M. Aspirin "resistance" and risk of cardiovascular morbidity systematic review and meta-analysis. Br Med J 336 (2008) 195-198
4. Snoep J., Hovens M., Eikenboom J., van der Bom J., and Huisman M. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. Arch Intern Med 167 15 (2007) 1593-1599
5. Lordkipanidze M., Pahrand C., Schampaert E., Turgeon J., Palisatis D.A., and Diodati J.G. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary heart disease. Eur Heart J 28 (2007) 1702-1708
6. Perneby C., Hakan Wallen N., Rooney C., Fitzgerald D., and Hjemdahl P. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 95 (2006) 652-658
7. Ivandic B.T., Giannitsis E., Schlick P., Staritz P., Katus H.A., and Hohlfeld T. Determination of aspirin responsiveness by use of whole blood platelet aggregometry. Clin Chem 53 (2007) 614-619
8. Poulsen T., Kristensen S., Atar D., and Mickley H. A critical appraisal of the phenomenon of aspirin resistance. Cardiology 104 (2005) 83-91
9. Dyskiewicz-Korpanty A.M., Frenkel E.P., and Sarode R. Approach to the assessment of platelet function: comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggreagation methods. Clin Appl Thromb/Hemost 11 1 (2005) 25-35
10. Gonzalez-Conejero R., Rivera J., Corral J., Acuna C., Guerrero J.A., and Vicente V. Biological assessment of aspirin efficacy on healthy individuals: heterogenous response or aspirin failure?. Stroke 36 (2005) 276-280
11. Ohmori T., Yatomi Y., Nonaka T., Kobayashi Y., Madoiwa S., Mimuro J., Ozakis Y., and Sakata Y. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signalling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 4 (2006) 1271-1278
12. Gengo F., Bates V., Rainka M., and Gengo M. Aspirin resistance in office patients treated for secondary stroke prophylaxis. Stroke 37 2 (2006) 715
13. Chakroun T., Addad F., Abderazek F., ben-Farhat M., Hamdi S., Gamra H., Hassine M., Ben-Hamda K., Samama M., and Elelamy I. Screening for aspirin resistance in stable coronary artery patients by three different tests. Thromb Res 121 3 (2007) 413-418
14. Gum P., Kottke-Marchant K., Poggio E., Gurm H., Welsh P., Brooks L., Sapp S., and Topol E. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
15. Gurbel P., Bliden K., DiChiara J., Newcomer J., Weng W., Neerchal N., Gesheff T., Chaganti S., Etherington A., and Tantry U. Evaluation of dose-related effects of aspirin on platelet function. Results from the Aspirin-Induced Platelet Effect (ASPECT) Study. Circulation 115 (2007) 3156-3164
16. Harrison P., Degal H., Blasbery K., Furtado C., Silver L., and Rothwell P. Screening for aspirin responsiveness after transient ischemic attack and stroke, comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 36 (2005) 1001-1005
17. Cattaneo M. Laboratory detection of 'aspirin resistance' what test should we use (if any)?. Eur Heart J 28 (2007) 1673-1675
18. Maree A., and Fitzgerald D. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 115 (2007) 2196-2207
19. Coomber B.L., Mitchell G.B., Starr A.E., Minhas K., Tamblyn A., Shewen P.E., and Gentry P.A. Clopidogrel induced suppression of bovine platelet activation in vitro and a preliminary study of its effect on the development of Mannheimia haemolytica induced pneumonia. Vet J 171 1 (2006) 126-134
20. Gasparyan A.Y., Watson T., and Lip G. The role of aspirin in cardiovascular prevention. J Am Coll Cardiol 51 (2008) 1829-1843
21. Din J., Newby D., and Flapan A. Omega 3 fatty acids and cardiovascular disease - fishing for a natural treatment. Br Med J 328 (2004) 30-35
22. Hooper L., Thompson R., Harrison R., Summerbell C., Ness A., Moore H., Worthington H., Durrington P., Higgins J., Capps N., Riemersma R., Ebrahim S., and Davey Smith G. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. Br Med J 332 7544 (2006) 752-760
23. Nair G., and Connolly S. Should patients with cardiovascular disease take fish oil?. Can Med Assoc J 178 2 (2008) 181-182
24. Mori T., Beilin L., Burke V., Morris J., and Ritchie J. Interactions between dietary fat, fish, fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscl Thromb Vascul Biol 17 2 (1997) 279-286
25. Pirich C., Gaszo A., Granegger S., and Sinzinger H. Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients. Thromb Res 96 3 (1999) 219-227
26. Engstrom K., Wallin R., and Saldeen T. Effect of low-dose aspirin in combination with stable fish oil on whole blood production of eicosanoids. Prostagland Leukot Essent Fatty Acids 64 6 (2001) 291-297
27. Horiuchi H. Recent advances in antiplatelet therapy: the mechanisms, evidence and approach to the problems. Ann Med 38 3 (2006) 162-172
28. Vermiere E. Patient adherence to therapy: 3 decades of research. J Clin Pharmacol Therap 26 (2001) 331-342
29. Biondi-Zoccai G., Lotrionte M., Agostoni P., Abbate A., Fusaro M., Burzotta F., Testa L., Sheiban I., and Sangiorgi G. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50279 patients at risk for coronary artery disease. Eur Heart J 27 (2006) 2667-2674
30. Lepantalo A., Mikkelsson J., Resendiz J.C., Viiri L., Backman J., Kankuri E., Karhunen P., and Lassila R. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 95 (2006) 253-259
31. Cohen H., Crandall J., Hailpern S., and Billett H. Aspirin resistance associated with HBA1c and obesity in diabetic patients. J Diab Comp 22 (2008) 224-228
32. Manoharan A., Gemmell R., and Hartwell T. Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy in patients with chromic myeloproliferative disorders. Am J Haematol 81 (2006) 676-683
33. 12 receptor. Clin Chem 52 3 (2006) 383-388